Skip to content

Differences in tumor microenvironment between MSS and MSI colorectal cancers

Differences in tumor microenvironment between MSS and MSI colorectal cancers

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500110744
Enrollment
Unknown
Registered
2025-10-20
Start date
2025-10-20
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Observation group of MSS/MSI colorectal cancer:None

Sponsors

Jiangsu Second Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Colorectal adenocarcinoma (primary lesion) was confirmed by histopathology; 2.Have confirmed microsatellite status as MSS or MSI (either) in the pathology report or molecular test and can consult the test report; 3.Usable and well-preserved FFPE tissue blocks or unstained sections; 4.The clinical data of the corresponding patients were traceable (including age, gender, date of surgery/harvesting, TNM stage, whether receiving ICI and follow-up outcome); 5.Permission to use samples/data for scientific research has been obtained;

Exclusion criteria

Exclusion criteria: 1.FFPE specimens could not be stained and analyzed for mIF due to poor preservation, massive antigen degradation, section necrosis/insufficient tissue or technical reasons; 2.The histological structure of the specimens was severely damaged and could not represent the original tumor microenvironment; 3.The origin of the specimen is unknown, or the judgment is confused by the combination of other primary tumors; 4.Clinical data were seriously missing to complete the primary analysis or to adjust for confounding factors;

Design outcomes

Primary

MeasureTime frame
Spatial distribution characteristics of the tumor microenvironment and types and proportions of immune cells;

Secondary

MeasureTime frame
Immunotherapy response and follow-up outcomes;

Countries

China

Contacts

Public ContactJin Heiying;Zhang Xiaochun

Jiangsu Second Hospital of Traditional Chinese Medicine

jinheiying70@163.com+86 25 8329 1202

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026